Modulation of TRAIL-induced tumor cell apoptosis in a hypoxic environment
暂无分享,去创建一个
W. El-Deiry | D. Dicker | L. Campbell | J. Plastaras | M. Ricci | P. Mayes
[1] P. V. van Diest,et al. HIF1-alpha overexpression indicates a good prognosis in early stage squamous cell carcinomas of the oral floor , 2005, BMC Cancer.
[2] Amato J Giaccia,et al. The role of p53 in hypoxia-induced apoptosis. , 2005, Biochemical and biophysical research communications.
[3] K. Nakanishi,et al. Expression of Hypoxia-Inducible Factor-1α Protein Predicts Survival in Patients with Transitional Cell Carcinoma of the Upper Urinary Tract , 2005, Clinical Cancer Research.
[4] P. Vaupel,et al. Hypoxia and anemia: effects on tumor biology and treatment resistance. , 2005, Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine.
[5] T. Burns,et al. Bnip3L is induced by p53 under hypoxia, and its knockdown promotes tumor growth. , 2004, Cancer cell.
[6] Clemencia Pinilla,et al. Cellular, Biochemical, and Genetic Analysis of Mechanism of Small Molecule IAP Inhibitors* , 2004, Journal of Biological Chemistry.
[7] W. El-Deiry,et al. Direct Repression of FLIP Expression by c-myc Is a Major Determinant of TRAIL Sensitivity , 2004, Molecular and Cellular Biology.
[8] A. Ashkenazi,et al. Targeting death receptors in cancer with Apo2L/TRAIL. , 2004, Current opinion in pharmacology.
[9] Moonil Kim,et al. Hypoxia Inhibits Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis by Blocking Bax Translocation , 2004, Cancer Research.
[10] J. Brown,et al. Exploiting tumour hypoxia in cancer treatment , 2004, Nature Reviews Cancer.
[11] A. Rustgi,et al. Targeting Bcl-xL in esophageal squamous cancer to sensitize to chemotherapy plus TRAIL-induced apoptosis while normal epithelial cells are protected by blockade of caspase 9 , 2004, Cell Death and Differentiation.
[12] C. Belka,et al. Influence of hypoxia on TRAIL-induced apoptosis in tumor cells. , 2004, International journal of radiation oncology, biology, physics.
[13] P. Maxwell,et al. HIF-1, An Oxygen and Metal Responsive Transcription Factor , 2004, Cancer biology & therapy.
[14] Clemencia Pinilla,et al. Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity. , 2004, Cancer cell.
[15] Wafik S El-Deiry,et al. TRAIL and apoptosis induction by TNF-family death receptors , 2003, Oncogene.
[16] A. Giaccia,et al. HIF-1 as a target for drug development , 2003, Nature Reviews Drug Discovery.
[17] G. Semenza. Targeting HIF-1 for cancer therapy , 2003, Nature Reviews Cancer.
[18] W. El-Deiry,et al. Flow cytometric analysis of tumor suppressor gene-induced apoptosis. , 2003, Methods in molecular biology.
[19] K. Peters,et al. Tirapazamine: a hypoxia-activated topoisomerase II poison. , 2002, Cancer research.
[20] D. Seol,et al. Hypoxia inhibition of apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). , 2002, Biochemical and biophysical research communications.
[21] Yahong Lin,et al. TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/DIABLO. , 2002, Genes & development.
[22] Adrian L. Harris,et al. Hypoxia — a key regulatory factor in tumour growth , 2002, Nature Reviews Cancer.
[23] W. el-Deiry,et al. Insights into cancer therapeutic design based on p53 and TRAIL receptor signaling , 2001, Cell Death and Differentiation.
[24] P. Vaupel,et al. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. , 2001, Journal of the National Cancer Institute.
[25] D. Dicker,et al. Enhanced TRAIL sensitivity by p53 overexpression in human cancer but not normal cell lines. , 2001, International journal of oncology.
[26] Michael T. Fisher,et al. Molecular determinants of response to TRAIL in killing of normal and cancer cells. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[27] G. Semenza,et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. , 2000, Genes & development.